Phase I (or Phase II) Dose-Ranging Clinical Trials: Proposal of a Two-Stage Bayesian Design

DOI10.1081/BIP-120017728zbMath1159.62348OpenAlexW2069317340WikidataQ44361082 ScholiaQ44361082MaRDI QIDQ4796210

Sylvie Chevret, Sarah Zohar

Publication date: 2 March 2003

Published in: Journal of Biopharmaceutical Statistics (Search for Journal in Brave)

Full work available at URL: https://doi.org/10.1081/bip-120017728

Mathematics Subject Classification ID

Applications of statistics to biology and medical sciences; meta analysis (62P10) Bayesian inference (62F15) Medical applications (general) (92C50) Sequential statistical design (62L05) Optimal stopping in statistics (62L15)

Related Items (2)

A system for determining maximum tolerated dose in clinical trial ⋮ Adaptive clinical trial designs for phase I cancer studies

Cites Work

• Continual Reassessment Method: A Practical Design for Phase 1 Clinical Trials in Cancer
• Monitoring Accumulating Data in a Clinical Trial
• Miscellanea. A stopping rule for the continual reassessment method
• Continual Reassessment Method: A Likelihood Approach
• A Strategy for Dose-Finding and Safety Monitoring Based on Efficacy and Adverse Outcomes in Phase I/II Clinical Trials
• Statistical Issues in Drug Development

This page was built for publication: Phase I (or Phase II) Dose-Ranging Clinical Trials: Proposal of a Two-Stage Bayesian Design